Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nilotinib
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Nilotinib in Treating Patients with Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCI-2012-02871, NCT01140568
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1284, NCI-2013-00469, 12-006178, NCT01806571
Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 and over
Trial IDs: Winship3143-16, NCI-2016-00162, IRB00087045, NCT02709083
Nilotinib and Cetuximab in Treating Patients With Solid Tumors That Can Be Treated With Cetuximab
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0039, NCI-2013-01168, NCT01871311
Nilotinib and Paclitaxel in Treating Patients with Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0086, NCI-2014-00688, 9659, NCT02379416
Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 64
Trial IDs: IRB00011766, NCI-2016-00083, NCT02779283
Start Over